Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.36 |
| ▸ | CDC25B | P30305 | 8/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.33 |
| ▸ | GJB2 | P29033 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532039 | 0.92 | TNK2 (0.33) | TNK2 | |
| SCHEMBL25826686 | 0.91 | PDE2A (0.36) | PTPN1CDC25BPDE2AHSPA5HTR1A | |
| SCHEMBL20144177 | 0.89 | PDE2A (0.36) | PTPN1CDC25BPDE2AHSPA5HTR1A | |
| SCHEMBL12243141 | 0.88 | PDE2A (0.37) | PTPN1CDC25BPDE2AHSPA5HTR1A | |
| SCHEMBL31063739 | 0.88 | PDE2A (0.37) | PTPN1CDC25BPDE2AHSPA5HTR1A | |
| SCHEMBL12393373 | 0.88 | PDE2A (0.37) | PTPN1CDC25BPDE2AHSPA5HTR1A | |
| SCHEMBL27086454 | 0.88 | PDE2A (0.37) | PTPN1CDC25BPDE2AHSPA5HTR1A | |
| SCHEMBL14039002 | 0.86 | PDE2A (0.37) | PTPN1CDC25BPDE2AHSPA5HTR1A | |
| SCHEMBL24158288 | 0.86 | PDE2A (0.37) | PTPN1CDC25BPDE2AHSPA5HTR1A | |
| SCHEMBL12393257 | 0.86 | PDE2A (0.37) | PTPN1CDC25BPDE2AHSPA5HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| WO-2021213288-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | 中国科学院上海药物研究所 (CN) | 2021-10-28 | — | — | WO | disclosed |
| US-RE46762-E1 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC (US) | 2018-03-27 | — | — | US | disclosed |
| US-8008264-B2 | 1′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021425-A1 | 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, MTAP, SLC29A1 | PTPN1 317/4885CDC25B 1492/4885PDE2A 2899/4885 |
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | PNP, TYMP, PIGS | PTPN1 2048/4885CDC25B 880/4885PDE2A 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.